Toggle navigation
DE
About Us
Our Services
Market Access
Benefit Assessment of Pharmaceuticals
AMNOG Price Negotiations
European Health Technology Assessment
Pathways to Reimbursement for Medical Devices
Reimbursement of Digital Health Applications
Reference Pricing for Pharmaceuticals
Loss of Exclusivity
Indirect Comparisons and Meta-Analyses
Clinical Trial Evaluation for the Early Benefit Assessment
Publications
Early Benefit Assessment
European Health Technology Assessment
Price Development
Negotiation
Indirect Comparisons and Meta-Analyses
Medical Devices
News
Current Benefit Assessments
Current European Health Technology Assessment Procedures
Contact
Current European Health Technology Assessment procedures
Ongoing
No entries available
Completed
Satralizumab
Elivaldogene autotemcel
Venetoclax
Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C
Alectinib
Brolucizumab
Canagliflozin
Cefiderocol
Crizanlizumab
Glasdegib
Midostaurin
Pazopanib
Polatuzumab vedotin
Pretomanid
Ramucirumab
Regorafenib
Siponimod
Sorafenib
Sotaglifozin
Ustekinumab
Vorapaxar
Preparation of live, attenuated varicella-zoster virus (Oka/Merck strain)
Please contact
Dr. Thomas Ecker
Phone +49 (40) 41 33 081-10
Current Benefit Assessments
Current European Health Technology Assessment Procedures
